Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

Group 1 - Company announced that its wholly-owned subsidiary, Ningbo Weierkaidi Medical Equipment Co., Ltd., received a medical device registration certificate from the Zhejiang Provincial Drug Administration for an "Electronic Endoscope Image Processor" [1] Group 2 - The product launch indicates a potential expansion in the medical device market, particularly in endoscopic technology [1]

Core Viewpoint - David Medical announced that its wholly-owned subsidiary, Ningbo Weier Kaidi Medical Equipment Co., Ltd., has received a medical device registration certificate from the Zhejiang Provincial Drug Administration for its electronic endoscope image processor, which enhances the company's product line and core competitiveness [1] Group 1 - The electronic endoscope image processor is designed to be used in conjunction with the company's electronic endoscopes, facilitating the display of images from endoscopic examinations on monitors [1] - The acquisition of the medical device registration certificate is expected to positively impact the company's future operational results [1] - The company is currently unable to predict the revenue impact of these products on future sales [1]

证券代码：300314 证券简称：戴维医疗 公告编号：2026-001 宁波戴维医疗器械股份有限公司 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日收到浙江 省药品监督管理局颁发的1项《医疗器械注册证》，具体如下： 一、医疗器械注册证的具体情况 产品名称：电子内窥镜图像处理器 注册证编号：浙械注准20262060003 批准日期：2025年12月31日 有效期至：2030年12月30日 注册分类：Ⅱ类 适用范围：产品与本公司生产的电子内窥镜配套使用，用于在内窥镜 诊断和/或治疗手术中与电子内窥镜连接，有效地在监视器上显示内窥镜观 察人体体腔的视场区域的图像。 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 维尔凯迪本次获注册的电子内窥镜图像处理器配套开发的电子内窥镜 产品使用。电子内窥镜图像处理器作为整套诊疗方案的"核心控制中枢"， 不仅具备高清图像采集、实时信号转化与传输功能，还可通过内置算法实 现图像增强、参数动态调节等辅助诊疗功能，为临床诊 ...

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

Core Insights - The Chinese open stapler market is experiencing a decline, with the market size decreasing from 15.3 billion yuan in 2020 due to the pandemic, and projected to reach 14.1 billion yuan in 2024, a year-on-year decrease of 2.1% [2] - The decline is attributed to the shift towards minimally invasive surgical techniques, with laparoscopic staplers becoming the mainstream due to their advantages such as less trauma and faster recovery [2] - Despite the decline, open staplers still hold irreplaceable value in grassroots medical settings and complex surgeries, indicating a potential stabilization in market size, although their market share is expected to continue decreasing [2] Industry Overview - Open staplers are primarily used in traditional open surgeries, offering advantages such as quick suturing, ease of use, single-use to prevent cross-infection, and fewer complications [3][4] - The types of open staplers include linear staplers, tubular digestive tract staplers, linear cutting staplers, anal staplers, purse-string staplers, curved cutting staplers, and skin staplers, each with specific applications [4] - The industry chain consists of upstream material suppliers, midstream manufacturers, and downstream consumers such as hospitals and clinics [6] Market Dynamics - The number of medical institutions in China is on the rise, projected to reach 1,093,600 by 2024, which will increase the demand for open staplers [8] - The competition in the open stapler market is shifting towards product upgrades and cost control as the market space contracts [10]

证券代码：300314 证券简称：戴维医疗 公告编号：2025-093 一、医疗器械注册证的具体情况 1、一次性使用套管穿刺器 型号、规格：PDE5、PDE10、PDE12、PDE15、PDK5、PDK10、PDK12、PDK15、 PDQ5、PDQ10、PDQ12、PDQ15 注册证编号：浙械注准20252022020 批准日期：2025年12月29日 宁波戴维医疗器械股份有限公司 关于全资子公司产品获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）全资子公司宁 波维尔凯迪医疗器械有限公司（以下简称"维尔凯迪"）于近日收到浙江 省药品监督管理局颁发的2项《医疗器械注册证》，具体如下： 器身型号规格：TCS-Plus 60、TCS-Plus 160、TCS-Plus 260；组件型 号规格：NRW30-2.5、NRW45-2.5、NRW60-2.5、NRW75-2.5等N系列，GRW30-2.5、 GRW45-2.5、GRW60-2.5、GRW75-2.5等G系列。 注册证编号：浙械注准2 ...

证券日报网讯 12月30日，戴维医疗发布公告称，天健会计师事务所作为公司2025年度财务报表和2025 年末财务报告内部控制审计机构，原委派唐彬彬（项目合伙人）和吕蔡霞作为公司签字注册会计师，刁 文杰作为项目质量控制复核人，为公司提供审计服务。由于天健会计师事务所内部工作调整，现委派卢 娅萍、卓雅心接替唐彬彬、吕蔡霞作为签字注册会计师，项目质量控制复核人保持不变，继续为公司提 供2025年度审计服务。变更后的签字注册会计师为卢娅萍（项目合伙人）、卓雅心，项目质量控制复核 人为刁文杰。 （文章来源：证券日报） ...

证券代码：300314 证券简称：戴维医疗 公告编号：2025-092 宁波戴维医疗器械股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 宁波戴维医疗器械股份有限公司（以下简称"公司"）于 2025 年 4 月 7 日召开了第五届董事会第十一次会议及第五届监事会第十一次会议， 并于 2025 年 5 月 6 日召开 2024 年度股东大会，分别审议通过了《关于续 聘 2025 年度审计机构的议案》，同意公司续聘天健会计师事务所（特殊 普通合伙）（以下简称"天健会计师事务所"）为公司 2025 年度财务报 表和 2025 年末财务报告内部控制审计机构。具体内容详见公司于 2025 年 4 月 9 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于续聘 会计师事务所的公告》（公告编号：2025-020）。 1、基本信息 项目合伙人、签字注册会计师:卢娅萍，2002 年起成为注册会计师， 2000 年开始从事上市公司审计，2002 年开始在天健会计师事务所执业， 2021 年起为公司提供审计服务； ...